Incorporating genetic data improves target trial emulations and informs the use of polygenic scores in randomized controlled trial design
Open Access
- 18 June 2025
- journal article
- research article
- Published by Springer Nature in Nature Genetics
- Vol. 57 (7) , 1620-1627
Abstract
Randomized controlled trials (RCTs) remain the gold standard for evaluating medical interventions, yet ethical, practical and financial constraints often necessitate reliance on observational data and trial emulations. This study explores how integrating genetic data can enhance both emulated and traditional trial designs. Using FinnGen (n = 425,483), we emulated four major cardiometabolic RCTs and showed how reduced differences in polygenic scores (PGS) between trial arms track improvement in study design. Simulation studies reveal that PGS alone cannot fully adjust for unmeasured confounding. Instead, Mendelian randomization analyses can be used to detect likely confounders. Finally, trial emulations provide a platform to assess and refine PGS implementation for genetic enrichment strategies. By comparing associations of PGS with trial outcomes in the general population and emulated trial cohorts, we highlight the need to validate prognostic enrichment approaches in trial-relevant populations. These results highlight the growing potential of incorporating genetic information to optimize clinical trial design.Keywords
Funding Information
- Broad Institute (Fellowship by the Eric and Wendy Schmidt Center)
This publication has 58 references indexed in Scilit:
- Use of Mendelian randomization to assess the causal status of modifiable exposures for rheumatic diseasesBest Practice & Research Clinical Rheumatology, 2024
- Reporting of Observational Studies Explicitly Aiming to Emulate Randomized TrialsJAMA Network Open, 2023
- Emulation of Randomized Clinical Trials With Nonrandomized Database AnalysesJAMA, 2023
- Target Trial EmulationJAMA, 2022
- Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision MakingClinical Pharmacology & Therapeutics, 2022
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal RiskJAMA, 2019
- Sulphonylurea monotherapy for patients with type 2 diabetes mellitus2013
- One‐to‐many propensity score matching in cohort studiesPharmacoepidemiology and Drug Safety, 2012
- Using Directed Acyclic Graphs to detect limitations of traditional regression in longitudinal studiesInternational Journal of Public Health, 2010
- Selective prescribing led to overestimation of the benefits of lipid-lowering drugsJournal of Clinical Epidemiology, 2006